Cargando…

Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer

BACKGROUND: Aberrated activation of cMet in gastric cancer contributes to tumor growth, angiogenesis and metastasis. cMet-overexpressing gastric cancer has a poor prognosis because of high tumor metastasis and limited therapeutic options. Luteolin is a common dietary flavonoid with antitumor propert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jun, Li, Guangliang, He, Kuifeng, Jiang, Weiqin, Xu, Cong, Li, Zhongqi, Wang, Haohao, Wang, Weibin, Wang, Haiyong, Teng, Xiaodong, Teng, Lisong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320638/ https://www.ncbi.nlm.nih.gov/pubmed/25638174 http://dx.doi.org/10.1186/s12967-015-0398-z

Ejemplares similares

Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models
por: Chen, Xiangheng, et al.
Publicado: (2018)

Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways
por: Wang, Haiyong, et al.
Publicado: (2017)

BP-1-102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways
por: Jiang, Xiaoxia, et al.
Publicado: (2019)

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study
por: Yu, Xiongfei, et al.
Publicado: (2022)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Giant appendiceal neurofibroma in von Recklinghausen’s disease: A case report and literature review
por: GUO, LIWEN, et al.
Publicado: (2014)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
por: Lohberger, Birgit, et al.
Publicado: (2021)

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases
por: Jin, Ketao, et al.
Publicado: (2011)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

Combining the Fibrinogen/Albumin Ratio and Systemic Inflammation Response Index Predicts Survival in Resectable Gastric Cancer
por: Zhang, Junbin, et al.
Publicado: (2020)

The Role of cMET in Gastric Cancer—A Review of the Literature
por: Van Herpe, Filip, et al.
Publicado: (2023)

COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2019)

LncRNA UCA1 in anti-cancer drug resistance
por: Wang, Haohao, et al.
Publicado: (2017)

Advances in the targeted therapy of liposarcoma
por: Guan, Zhonghai, et al.
Publicado: (2015)

HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018)

Antitumor effect of FP3 in a breast cancer xenograft model
por: LAN, HUANRONG, et al.
Publicado: (2013)

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor
por: Sakr, Hany I, et al.
Publicado: (2015)

Urinary cMet as a prognostic marker in immunoglobulin A nephropathy
por: An, Jung Nam, et al.
Publicado: (2020)

Prognostic Value of the Combination of CEA and Fibrinogen/Albumin Ratio in Resectable Gastric Cancer
por: Zhang, Junbin, et al.
Publicado: (2020)

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
por: Kim, Ki-Hyun, et al.
Publicado: (2017)

Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors
por: Collie, Gavin W., et al.
Publicado: (2019)

Renoprotective effects of a novel cMet agonistic antibody on kidney fibrosis
por: Kim, Yong Chul, et al.
Publicado: (2019)

Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
por: Ohara, Masahiro, et al.
Publicado: (2021)

The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
por: Armstrong, Gemma R., et al.
Publicado: (2021)

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
por: Machiraju, Devayani, et al.
Publicado: (2023)

Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet
por: Wu, Xiaoli, et al.
Publicado: (2019)

Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
por: Singh, Ratnakar, et al.
Publicado: (2019)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors
por: Gymnopoulos, Marco, et al.
Publicado: (2019)

EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming
por: Meng, Fanyan, et al.
Publicado: (2019)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
por: Kim, Yong Chul, et al.
Publicado: (2018)

cMet agonistic antibody attenuates apoptosis in ischaemia‐reperfusion–induced kidney injury
por: An, Jung Nam, et al.
Publicado: (2020)

LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling
por: Wang, Haiyong, et al.
Publicado: (2019)

Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis
por: Su, Xingyun, et al.
Publicado: (2016)

Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model
por: Xiao, Boduan, et al.
Publicado: (2017)

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
por: Van Der Steen, Nele, et al.
Publicado: (2015)

The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells
por: Jiang, Wen G., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rr37lk1hht19vpv89g4sos47pk